- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07829497
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Background:
Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause inflammation, damage body tissues, and change nerve signals in the brain. This can lead to ongoing pain that interferes with daily life. Researchers want to know more about how pain affects the lives of those with rheumatic diseases.
Objective:
To learn how the body and brain experience pain in people with and without rheumatic diseases.
Eligibility:
People aged 9 to 85 years with a diagnosed or suspected rheumatic disease and ongoing pain. They must be enrolled in protocols 01-AR-0227, 94-AR-0066, or 11-AR-0223. Healthy volunteers are also needed.
Design:
All participants will have an initial visit and may have up to 5 follow-up clinic visits spaced about 6 months apart. Each visit may last 3 to 4 hours. Patients with rheumatic diseases may have up to 2 more visits if they have a disease flare-up.
All participants will have these procedures at each visit:
Bedside quantitative sensory testing (B-QST): The participant's body will be touched with various probes: a cotton tip, a tuning fork, an ice-cold tuning fork, a heat probe, a device that applies pressure, and a probe with a sharp tip. These probes will not cause injury. Participants will describe how the touches feel and rate the intensity on a scale of 1 to 10.
Questionnaires: They will rate their overall health, quality of life, and any disease activity.
Research blood: Blood will be collected during the visits. Some blood will be used for how environmental factors affect our genes.
Physical exam and History review: They will provide information about their medical history and physical exam will be performed by a clinician.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Study Description:
Pain is one of the most common presenting complaints across all rheumatic diseases. Pain is often complex, and can be debilitating with symptoms resulting from a combination of underlying mechanisms, such as nociceptive pain, neuropathic pain, and nociplastic pain. A better characterization of pain in rheumatic diseases is needed to improve pain management. With this study we aim to better phenotype pain in rheumatic diseases by using patient reported outcomes and bedside quantitative sensory testing.
Objectives:
Primary Objective:
To gain a deeper understanding of the distinct pain mechanisms in rheumatic diseases to ultimately improve pain management and treatment outcomes for individuals with these conditions. To compare these measures with age- and sex-matched healthy controls.
Secondary Objectives:
- Explore associations between pain phenotypes and disease activity/progression.
- Investigate the impact of pain phenotypes on patient-reported outcomes (PROs) and quality of life (QOL) in comparison with the age and sex matched healthy volunteers
Endpoints:
Primary Endpoint:
Pain phenotype based on measurements from PRO's and bedside quantitative sensory testing (QST). Establish age- and sex-adjusted norms derived from healthy volunteers.
Secondary Endpoints:
- Explore associations between pain phenotypes and disease activity/progression. Investigate the impact of pain phenotypes on patient-reported outcomes (PROs) and quality of life (QOL).
- Establish an age- and sex-matched baseline for QOL. Patient demographics and standard measures of disease activity and damage are to be collected at the time of performing QST.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Lubna K Hooda, R.N.
- Número de telefone: (301) 480-1391
- E-mail: lubna.hooda@nih.gov
Estude backup de contato
- Nome: Sarfaraz A Hasni, M.D.
- Número de telefone: (301) 451-1599
- E-mail: hasnisa@mail.nih.gov
Locais de estudo
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- Recrutamento
- National Institutes of Health Clinical Center
-
Contato:
- Yenealem Temesgen-Oyelakin, B.S.N.
- Número de telefone: 301-451-4990
- E-mail: yenealem.temesgen-oyelakin@nih.gov
-
Contato:
- Lubna Hooda, B.S.N.
- Número de telefone: (301) 480-1391
- E-mail: lubna.hooda@nih.gov
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study team will contact participants who are 9 years and older and are enrolled in NIH protocols 01-AR-0227, 94-AR-0066, and 11-AR-0223, because affected participants in this study must have an established or suspected rheumatologic disease and must also be co-enrolled in one of these protocols. Healthy volunteers may include family members of participants enrolled in these studies. Potential participants may also be identified through the Office of Patient Recruitment, direct outreach to local rheumatologists, internists, and university hospital clinics, or referrals from health care providers. However, these individuals must first be enrolled in one of the NIH protocols listed above before joining this study.
Descrição
- INCLUSION CRITERIA
Inclusion Criteria for Subjects Suspected or Diagnosed with Rheumatic Diseases
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Aged 9-85 years
- Diagnosed or suspected of having a rheumatic disease.
- Ability of the subject to understand and the willingness to sign a written informed consent document or assent.
- Must be enrolled in one of the NIAMS protocols (01-AR-0227, 94-AR-0066, 11-AR-0223)
- To be able to answer PRO questionnaires in either English and/or Spanish languages.
Inclusion Criteria Healthy Volunteers
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Aged 9-85 years
- No known history of a rheumatic disease or any other chronic medical illness.
- Ability of the subject to understand and the willingness to sign a written informed consent document or assent.
- To be enrolled in either of the ongoing NIAMS protocols 01-AR-0227, 94-AR-0066, or 11-AR-0223.
- To be able to answer PRO questionnaires in either English and/or Spanish languages.
EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
- Treatment with investigational drug or other investigational intervention while enrolled in this study.
- Any physical exam finding that precludes bedside QST.
- Developmental delay or cognitive impairment that interfere with following or understanding the test instructions.
- Subjects using illicit or street drugs will be excluded. Subjects taking prescribed pain medications will not be excluded.
- Any chronic medical condition that may hinder participation in the study as determined by the study PI.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Adult patients
Who are suspected or diagnosed with rheumatic diseases |
It involves measuring a participant's response to standardized stimuli such as light touch, vibration, heat, cold, pressure, and sharp sensation. A qualified health professional will use various tools to stimulate the participant's nerves and record their response. |
|
Healthy adult volunteer
Who do not have or are not suspected to have rheumatic diseases |
It involves measuring a participant's response to standardized stimuli such as light touch, vibration, heat, cold, pressure, and sharp sensation. A qualified health professional will use various tools to stimulate the participant's nerves and record their response. |
|
Minor healthy volunteer aged 9 and above
Who do not have or are not suspected to have rheumatic diseases |
It involves measuring a participant's response to standardized stimuli such as light touch, vibration, heat, cold, pressure, and sharp sensation. A qualified health professional will use various tools to stimulate the participant's nerves and record their response. |
|
Minor patients aged 9 and above
Who are suspected or diagnosed with rheumatic diseases |
It involves measuring a participant's response to standardized stimuli such as light touch, vibration, heat, cold, pressure, and sharp sensation. A qualified health professional will use various tools to stimulate the participant's nerves and record their response. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain phenotype based on measurements from PRO's and bedside quantitative sensory testing (QST).
Prazo: Enrollment/baseline visit6 month visit (optional) 12 month visit (optional)18 month visit (optional) 24 month visit (optional)Unscheduled visit (optional)
|
Ratings of stimulus intensity and pain will be captured using a 0 (no sensation/no pain) to 10 (most intense sensation/pain imaginable) numerical rating scale. |
Enrollment/baseline visit6 month visit (optional) 12 month visit (optional)18 month visit (optional) 24 month visit (optional)Unscheduled visit (optional)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quality of life
Prazo: Enrollment/baseline visit6 month visit (optional) 12 month visit (optional)18 month visit (optional) 24 month visit (optional)Unscheduled visit (optional)
|
Patient questionnaires will be used to characterize pain and associated symptoms in participants across 10 core pain domains (pain intensity, pain interference, physical functioning, sleep, pain catastrophizing, depression, anxiety, global satisfaction with treatment, substance use screener, and quality of life). Age-specific measures will be utilized according to best practices when necessary. |
Enrollment/baseline visit6 month visit (optional) 12 month visit (optional)18 month visit (optional) 24 month visit (optional)Unscheduled visit (optional)
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Sarfaraz A Hasni, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Neuroinflamatórias
- Espondiloartrite Axial
- Doenças ósseas
- Doenças musculoesqueléticas
- Doenças bucais
- Doenças estomatognáticas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Doenças articulares
- Doenças do Tecido Conjuntivo
- Doenças autoimunes
- Doenças do sistema imunológico
- Infecções
- Doenças oculares
- Doenças Autoimunes do Sistema Nervoso
- Doenças da coluna vertebral
- Espondilartropatias
- Anquilose
- Xerostomia
- Doenças das Glândulas Salivares
- Síndromes do Olho Seco
- Doenças do Aparelho Lacrimal
- Espondilite
- Doenças Virais do Sistema Nervoso Central
- Infecções do Sistema Nervoso Central
- Encefalite
- Vasculite
- Vasculite, Sistema Nervoso Central
- Meningite
- Meningoencefalite
- Doenças da Pele e do Tecido Conjuntivo
- Artrite
- Lúpus Eritematoso Sistêmico
- Espondilartrite
- Espondilite Anquilosante
- Síndrome de Sjogren
- Artrite, Reumatóide
- Doenças Reumáticas
- Vasculite Lúpica, Sistema Nervoso Central
Outros números de identificação do estudo
- 10002670
- 002670-AR
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .